EQL Pharma ABOSTO:EQL -2.32%42 PEG Ratio is 2.15 as of Jul. 03, 2026, which is 94% above its 10-year median of 1.11. GuruFocus rates OSTO:EQL with a GF Score™ of 42/100. The stock has 4 warning signs investors should review. Among 349 Drug Manufacturers companies, EQL Pharma AB ranks worse than 56.73% on this metric.
* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
The historical rank and industry rank for EQL Pharma AB's PEG Ratio or its related term are showing as below:
OSTO:EQL'
s PEG Ratio Range Over the Past 10 Years
Min: 0.72 Med: 1.11 Max: 2.98
Current: 2.15
During the past 13 years, EQL Pharma AB's highest PEG Ratio was 2.98. The lowest was 0.72. And the median was 1.11.
OSTO:EQL's PEG Ratio is ranked worse than 56.73% of 349
companies
in the Drug Manufacturers industry
Industry Median: 1.71
vs OSTO:EQL: 2.15
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
EQL Pharma AB (OSTO:EQL) PEG Ratio Explanation
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
EQL Pharma AB PEG Ratio Related Terms
EQL Pharma AB PEG Ratio Historical Data
* Premium members only.
The historical data trend for EQL Pharma AB's PEG Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, EQL Pharma AB's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
EQL Pharma AB PEG Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, EQL Pharma AB's PEG Ratio distribution charts can be found below:
* The bar in red indicates where EQL Pharma AB's PEG Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
EQL Pharma AB (OSTO:EQL) has a PEG Ratio of 2.15 as of Jul. 03, 2026. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on EQL Pharma AB and its competitors. This is 94% above median its historical median of 1.11. Over the past decade, EQL Pharma AB's PEG Ratio has ranged from 0.72 to 2.98. According to the industry distribution chart, EQL Pharma AB ranks #198 out of 349 companies in the Drug Manufacturers industry, placing it in the top 56.7%.
Is EQL Pharma AB's PEG Ratio too high?
EQL Pharma AB's current PEG Ratio of 2.15 is 94% above median its 10-year median of 1.11. Over the past 10 years, this metric has ranged from a low of 0.72 to a high of 2.98. The Drug Manufacturers industry median PEG Ratio is 1.71. EQL Pharma AB's value of 2.15 is 25.7% above this industry median. Based on the distribution chart, EQL Pharma AB ranks #198 out of 349 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, EQL Pharma AB has a GF Score™ of 42/100, reflecting its overall financial health beyond just this single metric.
How does EQL Pharma AB's PEG Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, EQL Pharma AB ranks #198 out of 349 companies for PEG Ratio. This places EQL Pharma AB in the lower half of its industry. The industry median PEG Ratio is 1.71. EQL Pharma AB's value of 2.15 is 25.7% above this benchmark. Historically, EQL Pharma AB's own PEG Ratio has ranged from 0.72 to 2.98 over the past decade. While the company's 10-year median is 1.11 vs. the industry median of 1.71, EQL Pharma AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PEG Ratio for a Drug Manufacturers company?
The median PEG Ratio among Drug Manufacturers companies is 1.71, based on 349 companies in the industry. Companies in the top quartile (top 25%) have a PEG Ratio significantly above this median, while those in the bottom quartile fall well below. However, PEG Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. EQL Pharma AB's current PEG Ratio of 2.15 is 25.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PEG Ratio mean?
A high PEG Ratio can signal that a stock is expensive relative to its fundamentals. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on EQL Pharma AB and its competitors. For the Drug Manufacturers industry, the median PEG Ratio is 1.71 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. EQL Pharma AB's current PEG Ratio is 2.15, which is 94% above median its own 10-year median of 1.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is EQL Pharma AB stock overvalued right now?
EQL Pharma AB (OSTO:EQL) has a current PEG Ratio of 2.15. The current PEG Ratio is 2.15, which is 94% above median its 10-year median of 1.11 and 25.7% above the Drug Manufacturers industry median of 1.71. EQL Pharma AB's overall GF Score™ is 42/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PEG Ratio calculated?
PEG Ratio is calculated from a company's financial statements. For EQL Pharma AB (OSTO:EQL), the current PEG Ratio is 2.15 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
EQL Pharma AB is a pharmaceutical company focused on efficiently and thoughtfully developing and marketing generic drugs. The company operates in one segment, which is medicine. Its niche generics are divided into four parts based on four sales and marketing models: Retail, Hospital, Branded, and Tests. EQL Pharma specializes in identifying, developing, and selling generics, i.e., medicines that are medically equivalent to originator medicines. The company operates in Sweden, Denmark, Norway, Finland, the rest of Europe, and outside Europe, generating the majority of its revenue from Sweden.
42GF Score
Get the complete analysis for OSTO:EQL
PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:EQL has been successfully added to your 
